000 01402 a2200385 4500
005 20250517224309.0
008 ####s 0 0 eng d
022 _a2509-8020
024 7 _a10.1186/s41687-018-0054-5
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aUnger, Joseph M
245 0 0 _aPatient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).
_h[electronic resource]
260 _bJournal of patient-reported outcomes
_c2017
300 _a27 p.
_bdigital
500 _aPublication Type: Journal Article
700 1 _aGriffin, Katherine
700 1 _aDonaldson, Gary W
700 1 _aBaranowski, Karen M
700 1 _aGood, Margorie J
700 1 _aReburiano, Eunicia
700 1 _aHussain, Maha
700 1 _aMonk, Paul J
700 1 _aVan Veldhuizen, Peter J
700 1 _aCarducci, Michael A
700 1 _aHigano, Celestia S
700 1 _aLara, Primo N
700 1 _aTangen, Catherine M
700 1 _aQuinn, David I
700 1 _aWade, James L
700 1 _aVogelzang, Nicholas J
700 1 _aThompson, Ian M
700 1 _aMoinpour, Carol M
773 0 _tJournal of patient-reported outcomes
_gvol. 2
_gp. 27
856 4 0 _uhttps://doi.org/10.1186/s41687-018-0054-5
_zAvailable from publisher's website
999 _c28578281
_d28578281